| Private Placement / Financing Transactions
Neurona Therapeutics: The company raised $120 million of Series E venture funding in a deal led by Viking Global Investors and Cormorant Asset Management on February 8, 2024, putting the company’s pre-money valuation at $280 million. UCB Ventures, Spur Capital Partners, Berkeley Frontier Fund, SymBiosis Capital Management, LYFE Capital, The Column Group, Ysios Capital, Alexandria Venture Investments, UC Investments, Euclidean Capital, Sphera Funds Management, Schroders Capital and Willett Advisors also participated in the round. The company is an operator of a clinical-stage biotherapeutics company intended to develop regenerative neural cell therapies with single-dose curative potential for the treatment of chronic neurological disorders.
Ambience: The company raised $70 million of Series B venture funding in a deal led by Kleiner Perkins and OpenAI Startup Fund on February 6, 2024, putting the company’s pre-money valuation at $230 million. Optum Ventures, Memorial Hermann Foundation, Andreessen Horowitz and other undisclosed investors also participated in the round. The company is a developer of an artificial intelligence-powered medical scribe designed to capture the nuances of clinician-patient conversation in real-time into a comprehensive note.
Attralus: The company raised an additional $56 million of Series B venture funding in a deal led by Alpha Wave Global on February 6, 2024, putting the company’s pre-money valuation at $370 million. Bristol-Myers Squibb, venBio, Vivo Capital, Surveyor Capital, Logos Capital and Sarissa Capital Management also participated in the round. The company is a developer of immunotherapies and an imaging diagnostic platform designed for multiple systemic amyloid disease treatments.
Ezra: The company raised $21 million through a combination of Series A venture funding in a deal led by FirstMark Capital and Healthier Capital on February 7, 2024, putting the company’s pre-money valuation at $44 million. Allianz Life Ventures, Republic, Mana Ventures, Gaingels, Accomplice VC, Founders Future, Credo Ventures, LDV Capital, Seedcamp, Vlad Tenev, Anne Wojcicki, Esther Dyson and Stephen Schwarzman also participated in the round. The company is a developer of screening equipment designed to make early detection of cancer more accessible and affordable.
Aizon: The company raised $20 million of Series C venture funding in a deal led by NewVale Capital on February 8, 2024, putting the company’s pre-money valuation at $25 million. Atlantic Bridge Capital, Crosslink Capital, and Uncork Capital also participated in the round. The company is a developer of a data analytics and AI platform designed to improve pharma manufacturing processes.
Vektor Medical: The company raised $16 million of Series A venture funding in a deal led by Solas BioVentures and TVM Capital Life Science on February 5, 2024. The company is a developer of an advanced artificial intelligence-based technology designed for the analysis and mapping of cardiac arrhythmias.
Novasenta: The company raised $15 million of Series B venture funding from undisclosed investors on February 5, 2024, putting the company’s pre-money valuation at $63 million. The company is a developer of a pharmaceutical drug intended to provide immunotherapy treatment for cancer.
Pixee Medical: The company raised $15 million of Series B venture funding in a deal led by Relyens on February 8, 2024. UI Investissement, Innovacom, Angelor, and Bpifrance also participated in the round. The company is a medical technology business that provides computer-assisted surgical navigation tools using advanced computer vision, augmented reality, and artificial intelligence technologies.
Bionaut Labs: The company raised $12.8 million of Series B1 venture funding from Mayo Clinic, Khosla Ventures and Upfront Ventures on February 6, 2024, putting the company’s pre-money valuation at $110 million. OurCrowd also participated in the round. The company is a developer of a micro-robotic technology designed to provide physical access to any anatomic location in the body.
Athos Therapeutics: The company raised $7.5 million of venture funding from undisclosed investors on February 6, 2024. The company is a developer of a technology platform and therapeutics designed for patients with inflammatory bowel and autoimmune diseases.
myBIOS: The company raised an undisclosed amount of venture funding from Sparkalis on February 8, 2024. The company is a producer of protein-based biological molecules intended to provide solutions for the recombinant production of natural biomaterials and enzymes.
Nventric: The company raised an undisclosed amount of Series B venture funding from Devsisters Ventures, Heungkuk Securities and KDB Investment on February 6, 2024. Premier Partners, Lead Compass Investment, Quad Asset Management, Korea Development Bank and UTC Investment also participated in the round. The company is a developer of a medical device designed to remove blood clots that cause ischemic stroke.
|
